Dennis Lennartz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Xlife Sciences AG / Key word(s): Miscellaneous/Regulatory Approval16-Feb-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of.
23.01.2023 - Xlife Sciences AG / Key word(s): Miscellaneous Stifel initiates research coverage of Xlife Sciences 23.01.2023 / 07:00 CET/CEST The renowned investment bank Stifel commenced its research coverage of Xife Sciences (SIX: XLS). The corresponding .
Xlife Sciences AG / Key word(s): PatentXlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle 20.01.2023 / 07:00 CET/CESTXlife Sciences AG (SIX: XLS) announced today that its Swiss portfolio company Axenoll Life Sciences AG has been granted a stra.
Xlife Sciences AG / Key word(s): MiscellaneousXlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CESTXlife Sciences' (SIX: XLS) portfolio company inflamed pharma has launched a research project to develop a potential th.
Xlife Sciences AG / Key word(s): MiscellaneousPortfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CESTLysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Scienc.